Expertise in
138
conditions

Dr. Joyce Teng

Dermatology | Pediatrics
730 Welch Rd, 
Palo Alto, CA 
Offers Telehealth
Expertise in
138
conditions
730 Welch Rd, 
Palo Alto, CA 

Overview

Joyce Teng is a Dermatologist and a Pediatrics provider practicing medicine in Palo Alto, California.

Dr. Teng is highly rated in 138 conditions, according to our data. Her clinical expertise encompasses Lamellar Ichthyosis, Nonbullous Congenital Ichthyosiform Erythroderma, Nevoid Basal Cell Carcinoma Syndrome, Dowling-Meara Epidermolysis Bullosa Simplex, and Liver Embolization.

She is actively involved in clinical research, co-authoring 118 peer reviewed articles and participating in 10 clinical trials.

Specialties

Dermatology
Pediatrics

Licenses

Dermatology in CA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Contra Costa Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Health Plan of San Mateo
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Highmark
  • EPO
  • HMO
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Valley Health
  • HMO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Health Advantage
  • HMO
  • INSURANCE PLAN
  • MEDICARE DISCOUNT CARD
  • MEDICARE MAPD
View 17 Less Insurance Carriers -

Locations

730 Welch Rd, Palo Alto, CA 94304

Additional Areas of Focus

Dr. Teng has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Managed Access Programs for BYL719, Alpelisib
Managed Access Programs for BYL719, Alpelisib
Enrollment Status: Available
Publish Date: April 14, 2026
Intervention Type: Drug
Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis
Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
Enrollment Status: Completed
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drug: QTORIN rapamycin anhydrous gel
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase I/II, Closed Label, Randomized, Pilot Study for the Safety and Efficacy of TolaSure Gel, 5% w/w Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex (TAMES)
A Phase I/II, Closed Label, Randomized, Pilot Study for the Safety and Efficacy of TolaSure Gel, 5% w/w Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex (TAMES)
Enrollment Status: Completed
Publish Date: September 11, 2023
Intervention Type: Drug
Study Drug: TolaSure
Study Phase: Phase 1
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations
Enrollment Status: Completed
Publish Date: November 17, 2022
Intervention Type: Drug, Other
Study Drug: Sildenafil
Study Phase: Phase 2
Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations
Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations
Enrollment Status: Terminated
Publish Date: August 04, 2022
Intervention Type: Drug
Study Drug: VT30
Study Phase: Phase 1/Phase 2
A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)
A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)
Enrollment Status: Completed
Publish Date: March 09, 2022
Intervention Type: Drug
Study Drugs: Sirolimus, Vehicle
Study Phase: Phase 2
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Enrollment Status: Terminated
Publish Date: November 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

118 Total Publications

De Novo Germline L858R EGFR Variants and Generalized Acanthosis Nigricans.
De Novo Germline L858R EGFR Variants and Generalized Acanthosis Nigricans.
Journal: JAMA dermatology
Published: January 14, 2026
Similar Doctors
Expertise in
43
conditions
Dr. Dawn Siegel
Dermatology | Pediatrics
Expertise in
43
conditions
Dr. Dawn Siegel
Dermatology | Pediatrics
730 Welch Rd, 
Palo Alto, CA 
 (0.1 miles away)
541-296-7585
Languages Spoken:
English
See accepted insurances

Dawn Siegel is a Dermatologist and a Pediatrics provider practicing medicine in Palo Alto, California. Dr. Siegel is highly rated in 43 conditions, according to our data. Her clinical expertise encompasses PHACE Syndrome, Hemangioma, Aplasia Cutis Congenita, and Clouston Syndrome.

Expertise in
16
conditions
Dr. David Fiorentino
Dermatology
Expertise in
16
conditions
Dr. David Fiorentino
Dermatology

Stanford University Medical Center

450 Broadway St, 
Redwood City, CA 
 (3.8 miles away)
650-723-6316
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. David Fiorentino, MD is a Dermatologist in Redwood City, CA and has over 24 years of experience in the medical field. He graduated from Stanford University in 1998. He is affiliated with Stanford Health Care. Dr. Fiorentino is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Dermatomyositis, Scleroderma, Systemic Sclerosis (SSc), and Calcinosis. Dr. Fiorentino is board certified in Board Certification: American Board Of Dermatology, Dermatology (2002).

Expertise in
97
conditions
Dr. Kerri Rieger
Dermatology
Expertise in
97
conditions
Dr. Kerri Rieger
Dermatology

Stanford Hospital And Clinics

965 High St, 
Palo Alto, CA 
 (1.0 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances

Kerri Rieger is a Dermatologist practicing medicine in Palo Alto, California. Dr. Rieger is highly rated in 97 conditions, according to our data. Her clinical expertise encompasses Basal Cell Skin Cancer, Mycosis Fungoides, Melanoma, and Sebaceous Adenoma.

Frequently Asked Questions about Dr. Joyce Teng

How do I make an appointment with Dr. Joyce Teng?

You can book an appointment with Dr. Joyce Teng by calling their office at 608-263-6420. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joyce Teng a top-rated expert for Lamellar Ichthyosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joyce Teng is classified as an Elite expert for Lamellar Ichthyosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joyce Teng specialize in?

While Dr. Joyce Teng is a Dermatology, they have specific expertise in Lamellar Ichthyosis, Nonbullous Congenital Ichthyosiform Erythroderma, and Nevoid Basal Cell Carcinoma Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Joyce Teng participate in research or clinical trials?

Yes. Dr. Joyce Teng has published 118 articles and abstracts on conditions like Lamellar Ichthyosis. You can view a list of Dr. Joyce Teng's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Joyce Teng accept my insurance?

Dr. Joyce Teng accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 608-263-6420 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Teng's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 123 Advanced Conditions
View All 134 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile